RD
RDDA.F Dr. Reddy's Laboratories Limited
- Market cap
- EUR 10.9B
- P/E
- 42.3x
- P/B
- 2.99x
- ROE
- 7.1%
- Dividend yield
- 0.55%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is RDDA.F undervalued?
Graham numberRDDA.F trades 137.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dr. Reddy's Laboratories Limited fundamental analysis
No fundamental analysis for Dr. Reddy's Laboratories Limited yet.
Dr. Reddy's Laboratories Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished do…
Full company profileDr. Reddy's Laboratories Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dr. Reddy's Laboratories Limited annual financial statements (INR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 141B | 142B | 154B | 175B | 190B | 214B | 246B | 279B | 326B | 336B | 335B |
| Gross Profit | 78.4B | 76.3B | 83.4B | 94.0B | 103B | 114B | 169B | 164B | 190B | 177B | 165B |
| Operating Income | 13.6B | 12.0B | 19.6B | 32.8B | 33.0B | 37.0B | 51.7B | 65.3B | 72.0B | 50.1B | 31.7B |
| EBITDA | - | 26.8B | 35.5B | 31.5B | 45.8B | 48.9B | 74.4B | 88.4B | 96.7B | 79.2B | 61.9B |
| Net Income | 12.0B | 9.81B | 18.8B | 19.5B | 19.1B | 23.6B | 45.1B | 55.7B | 56.5B | 42.9B | 27.4B |
| EPS | 73 | 59 | 113 | 118 | 116 | 142 | 271 | 67 | 68 | 51 | 33 |
| Balance Sheet | |||||||||||
| Total Assets | 220B | 226B | 225B | 232B | 265B | 297B | 323B | 388B | 493B | 579B | 574B |
| Total Liabilities | 95.8B | 99.1B | 85.2B | 77.3B | 90.5B | 106B | 90.0B | 107B | 156B | 199B | 185B |
| Shareholders' Equity | 124B | 126B | 140B | 155B | 175B | 191B | 233B | 281B | 333B | 377B | 386B |
| Cash & Short-term Investments | 3.87B | 2.64B | 2.23B | 2.05B | 14.8B | 14.9B | 5.78B | 7.11B | 14.7B | 15.4B | 13.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5B | 18.0B | 28.7B | 29.8B | 35.7B | 28.1B | 58.9B | 45.4B | 46.4B | 56.8B | 8.71B |
| Capital Expenditure | 12.3B | 9.29B | 6.96B | 4.85B | 9.74B | 14.7B | 18.9B | 27.4B | 34.4B | 38.4B | 16.1B |
| Free Cash Flow | - | 6.99B | 21.2B | 23.7B | 23.1B | 9.06B | 40.0B | 18.0B | 12.0B | 18.3B | -7.34B |
| Ratios | |||||||||||
| ROE | 9.7% | 7.8% | 13.4% | 12.6% | 10.9% | 12.4% | 19.4% | 19.8% | 17.0% | 11.4% | 7.1% |
| ROA | 5.5% | 4.3% | 8.3% | 8.4% | 7.2% | 7.9% | 14.0% | 14.4% | 11.5% | 7.4% | 4.8% |
| Net Profit Margin | 8.5% | 6.9% | 12.2% | 11.2% | 10.1% | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% | 8.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dr. Reddy's Laboratories Limited dividends
- Dividend yield
- 0.55%
- Forward dividend
- 0.07 EUR
- Payout ratio
- 15.5%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | INR 6.66B | 8.00 | 15.5% |
| 2025 | INR 6.66B | 8.01 | 11.8% |
| 2024 | INR 6.65B | 7.98 | 11.9% |
| 2023 | INR 4.98B | 30 | 11.0% |
| 2022 | INR 4.15B | 25 | 17.6% |
| 2021 | INR 4.15B | 25 | 21.7% |
| 2020 | INR 3.31B | 20 | 17.0% |
| 2019 | INR 3.32B | 20 | 17.7% |
| 2018 | INR 3.32B | 20 | 33.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Nov 5, 2024.
Who owns Dr. Reddy's Laboratories Limited
- Insiders 0.00%
- Institutions 14.79%
- Public & others 85.21%
- Shares outstanding 834M
- Free float 3.59B
Dr. Reddy's Laboratories Limited company profile
- Company name
- Dr. Reddy's Laboratories Limited
- Ticker
- RDDA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 27,527
- Fiscal year end
- March
- Address
- 8-2-337, Road No. 3, Hyderabad, India, 500034
- Phone
- 91 40 4900 2900
- Website
- drreddys.com
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Limited management
10- Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management Council · born 1960
- Mr. Kallam Satish Reddy B.Tech., M.S.Chairman of the Board & Member of the Management Council · born 1967
- Mr. Erez Israeli M.B.A.CEO & Member of the Management Council · born 1968
- Mr. Mannam VenkatanarasimhamCFO & Member of the Management Council · born 1970
- Mr. Krishna K. Venkatesh B.Pharma M.S.Global Head of IPDO, Integrated Product Development & Member of the Management Council · born 1973
- Mr. Motupalli Venkata Ramana M.B.A.CEO of Global Generics & Member of Management Council · born 1969
- Mr. Sanjay Sharma B.Tech.Executive VP, COO & Member of Management Council · born 1968
- Mr. Patrick Aghanian B.A., M.B.A.Head of Consumer Health Organization & Member of Management Council · born 1965
- Mr. Bhethanabottla S. PhanimitraChief Digital & Information Officer and Member of the Management Council · born 1980
- Mr. Milan KalawadiaCEO of North America & Member of Management Council · born 1977